This question hits home for me. I recently sat down with the husband, and main caregiver, of a woman with advanced dementia. The woman eats very little and is losing weight despite her husband’s great efforts at encouraging her to eat. Under the care of another physician, she had been given megestrol acetate and there had been some improvement. Her visit to my office was an opportunity to continue an ongoing conversation with her husband about his wife’s overall decline, her advancing dementia, and the sorrow he was feeling over her failing health.
===Name of drug=== *Will be capitalized if it is a trade name (brand name) or uncapitalized if it is a generic name. *Two trade names that are nearly identical (eg Adalat PA and Adalat XL) need not have separate entries unless there is a particular reason for doing so. *Names will be listed alphabetically and broken into an appropriate number of pages (with 200-500??? items per page) Peg-Intron is the correct spelling that you have listed as Pegetron for pegylated interferaon alfa2b made by schering plough and marketed in the US for HCV
- mg/kg subcutaneously once a day
-Safety and effectiveness in pediatric patients with HIV have not been established.
-Somatropin clearance appears similar in adults and children, but no pharmacokinetic studies have been conducted in children with HIV.
-Two small studies (total of 16 patients) of up to 26 weeks duration showed therapy was well tolerated with safety observations consistent with the adult studies.
Use: Treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance